[go: up one dir, main page]

NO20081056L - Novel, heterocyclic NF-kB inhibitors - Google Patents

Novel, heterocyclic NF-kB inhibitors

Info

Publication number
NO20081056L
NO20081056L NO20081056A NO20081056A NO20081056L NO 20081056 L NO20081056 L NO 20081056L NO 20081056 A NO20081056 A NO 20081056A NO 20081056 A NO20081056 A NO 20081056A NO 20081056 L NO20081056 L NO 20081056L
Authority
NO
Norway
Prior art keywords
cycloalkyl
alkyl
hydroxyalkyl
heteroaryl
aryl
Prior art date
Application number
NO20081056A
Other languages
Norwegian (no)
Inventor
Johann Leban
Harald Schmitt
Kristina Wolf
Stefano Pegoraro
Andreas Wuzik
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/008261 external-priority patent/WO2006032322A1/en
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of NO20081056L publication Critical patent/NO20081056L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører forbindelser med den generelle formel (III) eller farmasøytisk akseptable salter derav med en syre eller en base, eller farmasøytisk akseptable prodroger eller en stereoisomer derav, R3 er H, -C(0)NRaRb, halogen, alkyl, halo-genalkyl, aryl, heteroaryl, OH5 SH,NR4OR5', NH2, amin, alkylamin, alkoksy, sykloalkyl, heterosyklo-alkyl, hydroksyalkyl eller halogenalkyloksy; R4 er H, halogen, alkyl, -C(NR7)NR7 R8, -(CH2)paryl, -(CH2)PNR7R8, -C(O)NR7R8, -N=CR7R8, -NR7C(O)R8, sykloalkyl, hetero-sykloalkyl, halogenalkyl, hydroksyalkyl, hydroksyalkylamino, alkylamino, heteroaryl eller aryl; R5 er halogen, alkyl, -C(NR7)NRrR8, -(CH2)paryl, -(CH2)pNR7R8, -C(O)NR7R8, -N=CR7R8, -NR7C(O)R8, sykloalkyl, hetero-sykloalkyl, halogenalkyl, hydroksyalkyl, hydroksyalkylamino, alkylamino, heteroaryl eller aryl.The present invention relates to compounds of the general formula (III) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof, R3 is H, -C (O) NRaRb, halogen, alkyl, halo- gene alkyl, aryl, heteroaryl, OH5 SH, NR4OR5 ', NH2, amine, alkylamine, alkoxy, cycloalkyl, heterocycloalkyl, hydroxyalkyl or haloalkyloxy; R4 is H, halogen, alkyl, -C (NR7) NR7 R8, - (CH2) paryl, - (CH2) PNR7R8, -C (O) NR7R8, -N = CR7R8, -NR7C (O) R8, cycloalkyl, hetero -cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl or aryl; R5 is halogen, alkyl, -C (NR7) NRrR8, - (CH2) paryl, - (CH2) pNR7R8, -C (O) NR7R8, -N = CR7R8, -NR7C (O) R8, cycloalkyl, hetero-cycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl or aryl.

NO20081056A 2005-07-29 2008-02-28 Novel, heterocyclic NF-kB inhibitors NO20081056L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/008261 WO2006032322A1 (en) 2004-09-20 2005-07-29 NOVEL HETEROCYCLIC NF-κB INHIBITORS
PCT/EP2006/002396 WO2007016979A2 (en) 2005-07-29 2006-03-15 NOVEL HETEROCYCLIC NF-κB INHIBITORS

Publications (1)

Publication Number Publication Date
NO20081056L true NO20081056L (en) 2008-02-28

Family

ID=36570358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081056A NO20081056L (en) 2005-07-29 2008-02-28 Novel, heterocyclic NF-kB inhibitors

Country Status (13)

Country Link
JP (1) JP2009502816A (en)
KR (1) KR20080031038A (en)
CN (1) CN101233119A (en)
AU (1) AU2006278998A1 (en)
BR (1) BRPI0614188A2 (en)
CA (1) CA2617225A1 (en)
EA (1) EA016300B1 (en)
IL (1) IL189112A0 (en)
NO (1) NO20081056L (en)
NZ (2) NZ565470A (en)
SG (1) SG172738A1 (en)
UA (1) UA97348C2 (en)
WO (1) WO2007016979A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005287692B2 (en) * 2004-09-20 2012-07-12 4Sc Ag Novel heterocyclic NF-kappaB inhibitors
BRPI0709595A2 (en) * 2006-03-15 2011-07-19 4Sc Ag heterocyclic nf-kapab inhibitors
EP2190843A1 (en) * 2007-09-19 2010-06-02 4Sc Ag Benzimidazole nf- kappab inhibitors
JP5780521B2 (en) 2008-05-28 2015-09-16 リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎ ＢｉｏＰｈａｒｍａ，Ｉｎｃ． Non-hormonal steroid modulators of NF-κB for treating diseases
LT2303021T (en) * 2008-06-16 2019-06-25 University Of Tennessee Research Foundation Compounds for the treatment of cancer
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2013082253A2 (en) * 2011-11-29 2013-06-06 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
CA2915566C (en) * 2013-06-18 2021-12-21 4Sc Discovery Gmbh 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors
TR201809440T4 (en) * 2014-01-29 2018-07-23 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation.
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
CN116113406B (en) * 2020-07-10 2025-08-29 密歇根大学董事会 GAS41 inhibitors and methods of use
CN120418231A (en) * 2022-12-30 2025-08-01 阿勒泰治疗公司 2-Substituted thiazole and benzothiazole compositions and methods as DUX4 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263508B (en) * 1991-02-12 1995-11-21 Pfizer
DK0870765T3 (en) * 1995-05-18 2004-02-23 Zeria Pharm Co Ltd Aminothiazole derivative, drug containing the same and intermediate for the preparation of the compound
JPH0987282A (en) * 1995-09-21 1997-03-31 Kyowa Hakko Kogyo Co Ltd Thiazole derivatives
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE19817459A1 (en) * 1998-04-20 1999-10-21 Basf Ag New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
DE19858593A1 (en) * 1998-12-18 2000-06-21 Merck Patent Gmbh (2-Phenyl-4-(phenylsulfonyl)-oxazol-5-yl)-amine therapeutic agents having 5-HT6 receptor affinity, useful for treating CNS disorders such as psychosis, schizophrenia, depression or Alzheimer's disease
NZ518420A (en) * 1999-11-05 2004-02-27 Sod Conseils Rech Applic Heterocyclic compounds having an inhibitory activity on calpains or a trapping activity on reactive oxygen species (ROS's) and their use as medicines
AU2002248432A1 (en) * 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
JP2005532983A (en) * 2001-09-26 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 3-Pyridyl or 4-isoquinolinyl thiazole as C17,20 lyase inhibitor
GB0130868D0 (en) * 2001-12-24 2002-02-06 Univ Strathclyde New compounds
EP1465613A2 (en) * 2002-01-10 2004-10-13 Boehringer Ingelheim Pharma GmbH & Co. KG Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
HRP20131159B1 (en) * 2002-09-30 2019-11-01 Bayer Ip Gmbh Fused azole-pyrimidine derivatives
GB0230162D0 (en) * 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis
FR2856685B1 (en) * 2003-06-25 2005-09-23 Merck Sante Sas THIAZOLYLPIPERIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
US20050209284A1 (en) * 2004-02-12 2005-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors
US20070293482A1 (en) * 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
AU2005287692B2 (en) * 2004-09-20 2012-07-12 4Sc Ag Novel heterocyclic NF-kappaB inhibitors

Also Published As

Publication number Publication date
CN101233119A (en) 2008-07-30
WO2007016979A3 (en) 2007-08-02
UA97348C2 (en) 2012-02-10
EA016300B1 (en) 2012-04-30
NZ588971A (en) 2012-06-29
BRPI0614188A2 (en) 2011-03-15
JP2009502816A (en) 2009-01-29
CA2617225A1 (en) 2007-02-15
SG172738A1 (en) 2011-07-28
NZ565470A (en) 2010-11-26
WO2007016979A2 (en) 2007-02-15
AU2006278998A1 (en) 2007-02-15
EA200800175A1 (en) 2008-08-29
IL189112A0 (en) 2008-08-07
KR20080031038A (en) 2008-04-07

Similar Documents

Publication Publication Date Title
NO20081056L (en) Novel, heterocyclic NF-kB inhibitors
WO2007104557A3 (en) Novel heterocyclic nf-kb inhibitors
MX2009008465A (en) 2-aminooxazolines as taar1 ligands.
EA201170096A1 (en) SUBSTITUTED PYRIMIDON DERIVATIVES
EA200970172A1 (en) PRINCIPLE OF CONNECTION AMIDA BOROIC ACID
NO20061419L (en) Triaza-spiropiperidine derivatives for use as Glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
AR060489A1 (en) BENZOAZEPIN ACID DERIVATIVES - OXI- ACETIC AS A PPAR - DELTA AGONIST USED TO INCREASE HDL-C, REDUCE LDL-C AND REDUCE CHOLESTEROL
AR058554A1 (en) HITEROCICLIC COMPOUNDS NITROGENATED OF 6 SUBSTITUTED MEMBERS, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY MGLUR5.
EP1724262A4 (en) 1-(2h)-isoquinolone derivative
TR201909709T4 (en) Benzodioxol derivatives as phosphodiesterase inhibitors.
ATE463483T1 (en) 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES AS ROCK-1 INHIBITORS
TW200505907A (en) Piperidine-benzenesulfonamide derivatives
AR076264A1 (en) SUBSTITUTED TRIAZOLOPIRIDINS AND ANALOGS OF THESE
EA200700141A1 (en) NEW AMINO-CYCLIC URINE DERIVATIVES, THEIR RECEIVING AND PHARMACEUTICAL APPLICATION AS KINASE INHIBITORS
PE20070051A1 (en) SERIN-AMIDAS SUBSTITUTED WITH HETEROAROIL
EA201591078A1 (en) PEPTIDES AS AN OXYTOCINE AGONISTS
EA201171000A1 (en) Derivative azaspranililkilkarbamatov in the form of 5-member heterocycles, the method of their production and use in therapy
AR086590A1 (en) CYCLHEXANONE AND HERBICIDE COMPOUNDS THAT UNDERSTAND THEM
EA200500717A1 (en) NEW IMIDAZOPIRIDINE CONNECTIONS, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR042002A1 (en) SUBSTITUTED BENZOXAZINONAS, OBTAINING PROCESS AND USES FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES.
PH12022550255A1 (en) 2-aminoquinazolinone derivative
AR049438A1 (en) DERIVATIVES WITH AROIL-O-PIPERIDINE STRUCTURE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND THERAPEUTIC APPLICATIONS
EA200801838A1 (en) NEW HETEROCYCLIC INHIBITORS NF-kB
PE20030705A1 (en) 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
ATE348813T1 (en) QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application